In the randomized,double-blind, placebo-controlled multicentre EMPA-RESPONSE-AHF trial theSGLT2-inhibitor empagliflozin had no beneficial effect on dyspnoe score, weight,NTproBNP levels within the observation period of up to day 4 after the indexevent as well as length of hospital stay but showed a reduced combined endpointof worsening HF, rehospitalization for HF or death at 60 days and a significantincrease in urinary output compared to placebo [54]. Here, NPPB is linked to hydrops fetalis.